HOME >> BIOLOGY >> NEWS
Support for chromosomal theory of cancer found in cancers' development of drug resistance

Berkeley Thirty-six years into the war on cancer, scientists have not only failed to come up with a cure, but most of the newer drugs suffer from the same problems as those available in the pre-war days: serious toxicity, limited effectiveness and eventual resistance.

This is no surprise to University of California, Berkeley, genetics researcher Peter Duesberg, professor of molecular and cell biology. According to his novel yet controversial "chromosomal" theory of cancer, which is receiving increased attention among cancer researchers, each cancer is unique, and there is no magic bullet.

"The mutation theory of cancer says that a limited number of genes causes cancer, so cancers should all be more or less the same," Duesberg said. The chromosomal theory, which he laid out in an article in the May 2007 issue of Scientific American, implies instead that, "even if cancers are from the same tissue, and are generated with the same carcinogen, they are never the same. There is always a cytogenetic and a biochemical individuality in every cancer."

The most that can be expected from a drug, he said, is that it is less toxic to normal cells than cancer cells, and that as a result a cancer detected early can be knocked back by chemotherapy. His chromosomal theory offers hope of early detection, however, since it ascribes cancer to chromosomal disruption, called aneuploidy, that can be seen easily through a microscope.

"By screening for aneuploidy, you could detect the cancer early and also see what possible drugs to use and whether drugs would even help," Duesberg noted. "Then, you wouldn't have to give a cocktail of drugs that includes all the best poisons, but you could leave out those you could tell wouldn't work. If you could cut chemotherapy drug toxicity in half or two-thirds, and direct it better at cancer, that is some progress. But it is not a cure."

Duesberg and colleagues discuss the major problem of drug resis
'"/>

Contact: Robert Sanders
rsanders@berkeley.edu
510-643-6998
University of California - Berkeley
27-Jun-2007


Page: 1 2 3 4

Related biology news :

1. Support for fragile X syndrome needed
2. Support groups aid women with breast cancer gene mutations
3. Changes in chromosomal constitution of preimplantation embryos suggest caution in genetic screening
4. Speeding the search for elusive chromosomal errors
5. What controls stickiness of smart chromosomal glue
6. New gene associated with Fanconi anemia explains hallmark chromosomal instability
7. Agilent Technologies announces breakthrough for cancer researchers studying chromosomal changes
8. Autism theory put to the test with new technology
9. New genetic data overturn long-held theory of limb development
10. Oregon researchers involved in new Clovis-age impact theory
11. Water theory is watertight, researchers say

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/10/2020)... ... ... Today CJ BIO announced the first in a series of Food Ingredient MasterClass webinars, ... revolutionizing ingredient mixes, nutritional content and flavor profiles across a range of savory foods ... AM (CDT) during SHIFT20, the virtual edition of the IFT Annual Meeting & Food ...
(Date:7/2/2020)... ... July 02, 2020 , ... ... a publication detailing the use of its revolutionary NEXTGENPCR endpoint thermocycler to ... in 16 minutes. The article, titled "Ultra-fast one-step RT-PCR protocol for the ...
(Date:6/28/2020)... (PRWEB) , ... June 25, ... ... of enterprise software solutions for biopharmaceutical R&D, today announced that it has ... developing innovative, full-length multispecific antibodies (Multiclonics®), to support their translational and clinical ...
Breaking Biology News(10 mins):
(Date:7/22/2020)... ... July 22, 2020 , ... Join experts from ... Sr. Manager Regulatory Solutions, in a one hour live webinar on Thursday, ... body in China for drugs and medical devices. Specifically, for medical devices, the NMPA ...
(Date:7/18/2020)... ... July 17, 2020 , ... dicentra , ... sciences and food industries, is pleased to announce that Charles Galea has joined ... Development. , Charles is an accomplished and results-driven sales executive with over 10 ...
(Date:7/10/2020)... ... 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology company ... Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. Nissenson will join ... Dr. Nissenson serves as an Emeritus Professor of Medicine at the David ...
(Date:7/1/2020)... ... June 29, 2020 , ... ... procured purchasing contracts to its membership, recently named BioFit Engineered Products ... the opportunity to purchase ergonomic seating, cafeteria tables, book trucks and carts at ...
Breaking Biology Technology:
Cached News: